($LTRN) Does It Make Sense for Lantern to Announce withZeta Before BIO2026?

Interesting timing question regarding withZeta.

Lantern's CEO, Panna Sharma, is scheduled to participate in a BIO2026 executive roundtable on June 23 focused on AI-driven drug development, biotech innovation, and the future of life sciences.

Given that management has repeatedly highlighted withZeta, discussed commercialization plans, and suggested it could become a meaningful value driver, I can't help but wonder:

Would management prefer to provide a withZeta update before such an event?

I'm not saying this guarantees anything.

However, if management views withZeta as a significant part of Lantern's future, having fresh news before or around BIO would seem strategically logical, especially when speaking with industry leaders, investors, and potential partners.

This is speculation on timing only, not a prediction of any specific announcement.

I'm simply trying to understand the timing.

Curious what others think. Coincidence, or could timing matter here?